Unity Biotechnology vs Rubedo Life Sciences

Unity Biotechnology was the marquee publicly traded senolytics company; after its lead eye drug failed and it was delisted from Nasdaq, its board approved a plan of dissolution in 2025.

Longevity

Rubedo Life Sciences

Clinical-stage developer of small-molecule senolytics that selectively clear pathologic senescent cells driving age-related disease.

For subscribers

Subscribe for the full comparison

Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.

Already subscribed? Sign in →